<i>In Vitro</i> Comparison of the Effect of Inhalation Delay and Flow Rate on the Emitted Dose from Three Valved Holding Chambers

Slator, Lois; Hollen, Dirk von; Sandell, Dennis; Hatley, Ross H.M.

doi:10.1089/jamp.2013.1061

Cited by 24 publications

(15 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although not explored in the current article, we have recently undertaken an extensive in vitro analysis of the effects of inhalation delays. (12) This analysis, which used a test setup similar to that of the present article, indicated that emitted dose increased with flow rate and decreased with lengthier inhalation delays. The antistatic VHCs tested were shown to have in vitro equivalence, whereas the conventional VHC had a more pronounced flow rate dependence.…”

Section: Limitations Of the Studymentioning

confidence: 63%

“…This is consistent with recent work from our group, which suggested that, when a conventional ''static'' VHC is used, drug delivery may be more vulnerable to the effect of inhalation delays, particularly at lower flow rates. (12) Notably, previous work comparing the lung deposition achieved by inhaling via a pMDI with VHC using a breathing maneuver and tidal breathing found that some benefit was conferred by undertaking the breathing maneuver. (3) However, the previous study used the conventional AC Plus VHC.…”

Section: Flow Ratesmentioning

confidence: 99%

“…The antistatic VHCs tested were shown to have in vitro equivalence, whereas the conventional VHC had a more pronounced flow rate dependence. (12) Separate from any effect of poor compliance, environmental factors, including extremes of temperature and humidity, are known to affect the performance of solution and suspension HFA pMDIs. (15) The current study was undertaken in ambient laboratory conditions, and therefore results may not be generalizable to other environments.…”

Section: Limitations Of the Studymentioning

confidence: 99%

See 2 more Smart Citations

In Vitro Characterization of the OptiChamber Diamond Valved Holding Chamber

Sandell³

et al. 2014

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Limitations Of the Studymentioning

confidence: 63%

Section: Flow Ratesmentioning

confidence: 99%

Section: Limitations Of the Studymentioning

confidence: 99%

See 1 more Smart Citation

In Vitro Characterization of the OptiChamber Diamond Valved Holding Chamber

Sandell³

et al. 2014

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Self Cite

View full text Add to dashboard Cite

show abstract

“…12,13 Another potential limitation of this study is that breathing simulation was not coupled to the measurement of particle size.…”

Section: Discussionmentioning

confidence: 99%

Effect of Interval Between Actuations of Albuterol Hydrofluoroalkane Pressurized Metered-Dose Inhalers on Their Aerosol Characteristics

Berlinski

Pennington

2017

Respir Care

View full text Add to dashboard Cite

BACKGROUND: Albuterol hydrofluoroalkane (HFA) either alone or with a valved holding chamber is used to treat bronchoconstriction. Delays between actuation and inhalation are common. Currently, the recommended interval between actuations of an albuterol HFA is 60 s. Using a shorter interval when multiple actuations are ordered will improve productivity in the hospital setting. METHODS: We studied aerosol characteristics of albuterol HFA (Ventolin, ProAir, and Proventil) with a cascade impactor calibrated at 30 L/min. We studied pressurized metered-dose inhalers (pMDI) alone, coupled to a nonelectrostatic valved holding chamber, and coupled to the valved holding chamber but introducing a 10-s delay between actuation and measurement. We tested intervals between actuations of 60, 30, and 15 s (not for delay scenario). The variable of most interest was fine-particle mass. Albuterol was measured by spectrophotometer (276 nm). RESULTS: Variations in fine-particle mass from 60-s values were < 15% for Ventolin and ProAir for all conditions tested and for Proventil with a valved holding chamber. Variations in fine-particle mass from 60-s values were > 15% for Proventil (pMDI alone with a 30-s interval and pMDI/valved holding chamber with delay and a 30-s interval). Adding a valved holding chamber increased fine-particle mass for all brands (ProAir 7-12%, Ventolin 26 -35%, and Proventil 44 -47%). The introduction of a 10-s delay reduced fine-particle mass for all brands (ProAir 34 -39%, Ventolin 39 -42%, and Proventil 27-32%). Comparison of fine-particle mass among brands showed that Proventil was > ProAir > Ventolin. CONCLUSIONS: Decreasing the interval between actuations from 60 to 30 and 15 s does not seem to affect the aerosol characteristics of ProAir and Ventolin. Although some changes were noticed for Proventil, the pMDI outperformed Ventolin that had the lowest fineparticle mass. The use of a valved holding chamber increased fine-particle mass, but introducing a 10-s delay between actuation and inhalation significantly reduced fine-particle mass.

show abstract

“…One recognized approach for adapting devices for tidal breathing is the use of a valved holding chamber with a pMDI [65]. However, the emitted dose can be compromised if the device is not used correctly, such as delayed inhalation after the act of firing [66]. To overcome this remaining issue of coordination, dry powder formulations have been developed that use various excipients, typically in a spray-drying process, to create drug particle formulations with high flowability [67].…”

Section: Compliance (Correct Technique)mentioning

confidence: 99%

Opportunities in Respiratory Drug Delivery

Pritchard

Giles²

2014

Ther. Deliv.

View full text Add to dashboard Cite

A wide range of asthma and chronic obstructive pulmonary disease products are soon to be released onto the inhaled therapies market and differentiation between these devices will help them to gain market share over their competitors. Current legislation is directing healthcare towards being more efficient and cost-effective in order to continually provide quality care despite the challenges of aging populations and fewer resources. Devices and drugs that can be differentiated by producing improved patient outcomes would, therefore, be likely to win market share. In this perspective article, the current and potential opportunities for the successful delivery and differentiation of new inhaled drug products are discussed.

show abstract

In Vitro Comparison of the Effect of Inhalation Delay and Flow Rate on the Emitted Dose from Three Valved Holding Chambers

Abstract: The different inhalation delays and flow rates had similar effects on the delivery of drug via the three VHCs. The two antistatic VHCs were shown to be equivalent in vitro in terms of emitted dose of albuterol.

Cited by 24 publications

References 11 publications

In Vitro Characterization of the OptiChamber Diamond Valved Holding Chamber

In Vitro Characterization of the OptiChamber Diamond Valved Holding Chamber

Effect of Interval Between Actuations of Albuterol Hydrofluoroalkane Pressurized Metered-Dose Inhalers on Their Aerosol Characteristics

Opportunities in Respiratory Drug Delivery

Contact Info

Product

Resources

About